Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Tine Ginnerup Andreasen, Trine Strandgaard, Tessa Jane Divita, Kristine Young-Halvorsen, Kristine Young‐Halvorsen, Anders Neijber, Tine G. Andreasen, Lars Dyrskjøt
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update
10.1016/j.eururo.2024.07.027 · 2024
Hexaminolevulinate in the management of nonmuscle invasive bladder cancer: a meta-analysis
2019
Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis
10.1136/bmjopen-2018-028173 · 2019
Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis
10.1111/bju.16364 · 2024
Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis
10.3390/cancers13174378 · 2021
Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis
10.1017/s0266462310001364 · 2011
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data
10.1016/j.eururo.2013.03.059 · 2013
Bladder cancer
10.1038/s41572-023-00468-9 · 2023
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
10.1038/s41585-018-0055-4 · 2018
The mechanism of action of BCG therapy for bladder cancer–a current perspective
10.1038/nrurol.2014.15 · 2014
Antitumor effect and induced immune response following exposure of hexaminolevulinate and blue light in combination with checkpoint inhibitor in an orthotopic model of rat bladder cancer
10.3390/biomedicines10030548 · 2022
Immune contexture changes following blue light cystoscopy with hexaminolevulinate in bladder cancer
10.1016/j.euros.2023.10.007 · 2023
Intravesical anti-PD-1 immune checkpoint inhibition treats urothelial bladder cancer in a mouse model
10.1097/ju.0000000000001576 · 2021
Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Guérin failure in patients with non-muscle-invasive bladder cancer
10.1016/j.eururo.2022.09.008 · 2022
Expression of PD-1 and PD-L1 in BCG-treated NMIBC
10.1177/23523735251368683 · 2025
TNF/TNFR superfamily members in costimulation of T cell responses-revisited
10.1146/annurev-immunol-082423-040557 · 2025
Gene expression markers of Tumor Infiltrating leukocytes
10.1186/s40425-017-0215-8 · 2017
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – a target for novel cancer therapy
10.1016/j.ctrv.2017.11.007 · 2018
The multiple faces of CCL13 in immunity and inflammation
10.1007/s10787-013-0177-5 · 2013
The VEGF/VEGFR axis revisited: implications for cancer therapy
10.3390/ijms232415585 · 2022
T cell exhaustion
10.1038/ni.2035 · 2011
Photodynamic therapy for bladder cancers, a focused review†
10.1111/php.13726 · 2023
Photodynamic diagnosis and therapy in non-muscle-invasive bladder cancer
10.3390/cancers16132299 · 2024
No additional external references are available.